Diversified Healthcare Trust

The stock is in a Stage 2 advancing corrective reset within a broader uptrend, and we maintain a bullish medium-term bias despite recent exhaustion at marginal highs. Price is pulling back into the rising 9/21 EMA zone above the 50 DMA, offering a structurally appropriate entry area. Short-term timing is neutral as EMAs flatten and momentum shows caution. We will Stalk the pullback for a confirmed bounce at EMAs before committing to a position.

• ↑Q1 revenue $379.6M (+5.6% YoY); normalized FFO $33.1M ($0.14/sh)
• ↑Same-property NOI rose 13.5% YoY to $44.3M
• ↓Compensation expenses 240bp above portfolio average, pressuring margins